FDA clears Haemonetics' cell-washing capabilities:
This article was originally published in Clinica
The US FDA has given Haemonetics' approval to broaden the use of its ACP 215 blood processing system to include a protocol for red blood cell washing. Previously cleared for freezing and thawing of red cells, the system can now allow doctors to remove more than 99% of plasma proteins from red blood cells derived from whole blood in a fully automated, closed system that supports good manufacturing practices, says the Braintree, Massachusetts firm. Plasma proteins can increase adverse patient reactions. The ACP 215 system reduces the labour involved with traditional red cell washing methods.